PT-141
Melanocortin Receptor Agonist · Sexual Dysfunction Treatment
Melanocortin receptor agonist with FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its action is central, in the nervous system, triggering sexual arousal pathways that do not depend on the vascular mechanisms behind traditional ED medications.
Overview
Melanocortin receptor agonist with FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its action is central, in the nervous system, triggering sexual arousal pathways that do not depend on the vascular mechanisms behind traditional ED medications.
Melanocortin receptors (MC3R/MC4R) in the central nervous system are activated selectively, and sexual arousal pathways are triggered independently of peripheral vascular mechanisms. Onset falls within 45 minutes; effects last 6–12 hours.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Carries FDA approval for treating HSDD in premenopausal women.
Effective in men through CNS pathways, PDE5 inhibitor-resistant cases included.
In women, desire and sexual arousal are enhanced.
Distress tied to low sexual desire falls.
Clinical trials report enhanced satisfaction.
- Class
- Melanocortin receptor agonist
- Research status
- FDA approved
- Half-life
- ~2.7 h
- Typical dose
- Women: 1.75 mg (FDA-approved); men: 1–2 mg; 0.5 mg test dose
- Frequency
- As needed before sexual activity; maximum 1 dose per 24 hours
- Cycle length
- As needed
- Storage
- Refrigerate at 2-8°C, use reconstituted solution within 30 days
Molecular data
- Type
- Melanocortin receptor agonist
- Half-life
- 162 min
Levels in single-dose multiples. A shape, not a pharmacokinetic prediction.
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Female HSDD (FDA-approved) | SubQ | 1.75mg | As needed, max 1 dose/24hr |
| Male Erectile Dysfunction | SubQ | 1-2mg | As needed, 45-60min before activity |
| Female Arousal Disorder | SubQ | 0.75-1.25mg | As needed, max 1 dose/24hr |
| Low Starting Dose | SubQ | 0.5mg | Test dose for tolerance assessment |
| Male ED - Standard | Nasal | 1.5-2mg | As needed, 30-45min before |
| Female Sexual Dysfunction | Nasal | 1-1.5mg | As needed, max 1 dose/24hr |
Interactions
PT-141 acts centrally, PDE5 inhibitors peripherally; additive BP effects warrant monitoring.
Two melanocortin agonists; combined, the risk is excessive activation and side effects.
Blood pressure can fall transiently under PT-141; close monitoring applies.
BP falls and flushing occurs with both; intake should be limited so hypotension does not become excessive.
Severe hypotension is the risk; contraindicated alongside heart condition medications.
Mechanisms differ; no interactions known.
Different pathways that may act synergistically on sexual dysfunction.
Pathways differ — melanocortin against GnRH — with no receptor overlap, though BP effects warrant monitoring.
What to expect
Safety
Mechanistic flags — properties of the pathway, not observed adverse events.
- Nausea (40%)
- Flushing (20%)
- Headache (11%)
- Injection site reactions
- Nausea or vomiting, severe or persistent
- Dizziness, or a significant drop in blood pressure
- Irregular heartbeat or chest pain
- Erection prolonged past 4 hours
- Severe headache, or a change in vision
- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy or breastfeeding
- Nitrate medications in use
Quality checklist
What to confirm before trusting a batch of research material. A verification aid — not an endorsement of any supplier.
- Third-party Certificate of AnalysisIndependent lab · dated · lot-matched.
- HPLC purity ≥ 98%Reverse-phase trace included.
- Mass-spec identity confirmedMALDI-TOF or ESI-MS.
- Counterion stated (acetate ≫ TFA)TFA salts can confound bioassays.
- Endotoxin / sterility statementRelevant once reconstituted.
- Lyophilised · cold-chain shippedStored −20 °C, shipped on ice.
- Labelled “research use only”No therapeutic or dosing claims.
Recorded signals for this compound · 8
- ✓Pharmaceutical grade with FDA approval (Vyleesi), from a licensed pharmacy
- ✓Powder white and crystalline (pure PT-141)
- ✓Solution clear on reconstitution
- ✓Labeling correct, with concentration and purity given
- !Compounded versions: the pharmacy licensed and following USP standards
- ×Appearance colored or oily, indicating impurities or degradation
- ×Source unknown, quality documentation missing
- ×Solution cloudy once reconstituted
FAQ
How does PT-141 differ from Viagra when both treat erectile dysfunction?
The mechanisms are entirely separate. Viagra (sildenafil) acts peripherally, dilating blood vessels in the penis through PDE5 inhibition. PT-141 acts centrally, in the brain, using melanocortin receptors to trigger sexual desire and arousal independent of blood flow. Because the vascular system is bypassed entirely, PT-141 can work even in PDE5 inhibitor-resistant cases.
Why is nausea seen in 40% of PT-141 users?
Melanocortin receptor activation is broad across the brain, not confined to sexual arousal centers. Off-target activation in nausea-control areas is a known side effect. An anti-nausea medication 30 minutes beforehand is the recommended countermeasure and reduces this significantly. Many users judge the pre-medication worth the benefit.
Is PT-141 used by women, or only by men?
Women use it. The FDA-approved indication is HSDD in women (hypoactive sexual desire disorder) at 1.75 mg; men use 1–2 mg for ED. The mechanism is identical either way — sexual arousal rises in both sexes through melanocortin receptor activation. Few drugs for sexual enhancement have efficacy proven specifically in women; this is one of them.
Is PT-141 safe in high blood pressure?
No. Blood pressure rises and flushing occurs. Uncontrolled hypertension is listed as a contraindication. Close BP monitoring applies where hypertension is present, and combination with blood pressure-lowering medications is to be avoided. Nitrates are specifically contraindicated, given the risk of severe hypotension.
References
- 1Double-Blind, Placebo-Controlled Evaluation of Intranasal PT-141 in Healthy Males and Patients with Erectile DysfunctionDiamond LE, Earle DC, Rosen RC, et al. · Urology · 2004
Intranasal PT-141 produced dose-dependent increase in erectile activity at doses >7mg, with onset in ~30 minutes. Safe and well-tolerated in both healthy men and ED patients.
Human RCTPubMed 14963471 ↗ - 2Salvage of Sildenafil Failures with Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled StudySafarinejad MR · Journal of Urology · 2008
342 men with ED unresponsive to sildenafil randomized to 10mg bremelanotide intranasal spray vs placebo. Demonstrated effectiveness in PDE5 inhibitor-resistant cases.
Human RCTPubMed 18206919 ↗ - 3Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology · 2019
Two identical phase 3, randomized, double-blind, placebo-controlled trials (NCT02333071 and NCT02338960). Bremelanotide 1.75mg SubQ significantly improved sexual desire and reduced related distress in premenopausal women with HSDD.
Human RCTPubMed 31599840 ↗ - 4The Neurobiology of Bremelanotide for the Treatment of HSDD in Premenopausal WomenClayton AH, Kingsberg SA, Goldstein I, et al. · CNS Spectrums · 2021
Bremelanotide activates MC4R in the medial preoptic area of the hypothalamus, increasing dopamine release. CNS mechanism of action independent of peripheral vascular effects.
ReviewPubMed 33455598 ↗
Pooled safety data from the full bremelanotide clinical development programme found adverse events emerging on treatment to be mostly mild or moderate; nausea occurred in 40%, flushing in 20% and headache in 11%.
A review of bremelanotide, the sole FDA-approved on-demand therapy for hypoactive sexual desire disorder, summarising evidence of increased desire and lessened distress.